Trilaciclib
Trilaciclib is a first-in-class CDK4/6 inhibitor that transiently arrests hematopoietic stem and progenitor cells in G1 phase before chemotherapy administration, thereby protecting bone marrow from chemotherapy-induced damage. It is used to decrease the incidence of chemotherapy-induced myelosuppression in adults receiving certain chemotherapy regimens for small cell lung cancer. Its myeloprotective mechanism distinguishes it from CDK4/6 inhibitors used as antineoplastic agents.
分子量
446.5000 g/mol
LogP
2.60
TPSA
91.20 Ų
Lipinski 五规则
符合
治疗领域
作用机制
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.
二维结构
Cite this structure
Embed this structure
SMILES
CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1
InChI
InChI=1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)
Molecular Formula
C24H30N8O
HBD / HBA
2 / 7
可旋转键数
3
重原子数
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
Trilaciclib is a first-in-class CDK4/6 inhibitor that transiently arrests hematopoietic stem and progenitor cells in G1 phase before chemotherapy administration, thereby protecting bone marrow from chemotherapy-induced damage. It is used to decrease the incidence of chemotherapy-induced myelosuppression in adults receiving certain chemotherapy regimens for small cell lung cancer. Its myeloprotective mechanism distinguishes it from CDK4/6 inhibitors used as antineoplastic agents.
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.
Yes, Trilaciclib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3894860. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 68029831. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="trilaciclib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/trilaciclib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/trilaciclib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/trilaciclib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="trilaciclib"></drugfyi-drug>